Literature DB >> 34359795

Present and Future Research on Anal Squamous Cell Carcinoma.

Laurie Spehner1,2, Jihane Boustani3, Luc Cabel4, Jérôme Doyen5, Angélique Vienot1,2,6, Christophe Borg1,2,6, Stefano Kim1,2,6,7.   

Abstract

Squamous cell carcinoma of the anus is an orphan disease, and after more than three decades of no substantial advances in disease knowledge and treatment, it is finally gaining momentum with the arrival of a taxane-based chemotherapy and immunotherapy. Currently, about 20 combination clinical trials with an anti-PD1/L1 are ongoing in localized and advanced stages, in association with radiotherapy, chemotherapy, tumor vaccines, anti-CTLA4, anti-EGFR, or antiangiogenic molecules. Moreover, a new biomarker with high sensitivity and specificity such as HPV circulating tumor DNA (HPV ctDNA) by liquid biopsy, is improving not only the prognostic measurement but also the treatment strategy guidance for this disease. Finally, better understanding of potential targets is reshaping the present and future clinical research in this unique, HPV genotype-16-related disease in the great majority of patients.

Entities:  

Keywords:  anal carcinoma; biomarkers; chemotherapy; immunotherapy; research; trials

Year:  2021        PMID: 34359795     DOI: 10.3390/cancers13153895

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  5 in total

1.  Research on Anal Squamous Cell Carcinoma.

Authors:  Krishan R Jethwa; Christopher L Hallemeier
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

2.  Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.

Authors:  Athénaïs Grave; Julie Blanc; Berardino De Bari; Mandy Pernot; Fatiha Boulbair; Monique Noirclerc; Angélique Vienot; Stefano Kim; Christophe Borg; Jihane Boustani
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

3.  A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.

Authors:  Magali Rebucci-Peixoto; Angélique Vienot; Olivier Adotevi; Marion Jacquin; Francois Ghiringhelli; Christelle de la Fouchardière; Benoit You; Tristan Maurina; Elsa Kalbacher; Fernando Bazan; Guillaume Meynard; Anne-Laure Clairet; Christine Fagnoni-Legat; Laurie Spehner; Adeline Bouard; Dewi Vernerey; Aurélia Meurisse; Stefano Kim; Christophe Borg; Laura Mansi
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

4.  Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.

Authors:  Stefano Kim; Jihane Boustani; Dewi Vernerey; Véronique Vendrely; Ludovic Evesque; Eric Francois; Laurent Quero; Francois Ghiringhelli; Christelle de la Fouchardière; Laëtitia Dahan; Oliver Bouché; Benoist Chibaudel; Farid El Hajbi; Chloé Vernet; Magali Rebucci-Peixoto; Alexandra Feuersinger; Christophe Maritaz; Christophe Borg
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

Review 5.  Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted.

Authors:  Reem Ali; Mustapha Aouida; Abdallah Alhaj Sulaiman; Srinivasan Madhusudan; Dindial Ramotar
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.